Pharming Group N.V. announces its participation in the 36th annual Oppenheimer Healthcare Life Sciences Conference, which will be held virtually on February 25 and 26, 2026. The company's CEO and Chief Medical Officer will present the company's work.
Pharming Group will take part in the 36th annual Oppenheimer Healthcare Life Sciences Conference, scheduled virtually on February 25 and 26, 2026. Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, Chief Medical Officer, will present the company's activities on Wednesday, February 25 at 12:40 PM Eastern Standard Time / 6:40 PM Central European Time. A live broadcast and a recording of the presentation will be available in the 'Upcoming Events' and 'News' sections of Pharming's website.
Investor Meetings
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Investors wishing to arrange a one-on-one meeting with Pharming's management team can contact their Oppenheimer representative. The company is a global biopharmaceutical enterprise based in Leiden, the Netherlands, dedicated to developing and marketing innovative medicines for patients suffering from rare, debilitating, and potentially life-threatening diseases.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 162,7 millions de dollars
Quarterly revenue: 162,7 millions de dollars
Revenue growth: -6 %
EBITDA: 2,4 millions de dollars
Net income: -3,6 millions de dollars
Risks mentioned
Baisse de 12 % des revenus RUCONEST sur le semestre, tirée par les volumes
Perte opérationnelle de 3,6 M$ contre un profit de 3,8 M$ un an plus tôt
Dépréciations de stocks portées à 16,6 M$ au bilan au 30 juin 2026
Opportunities identified
Progression de 37 % des revenus Joenja au premier semestre 2026
Autorisation de mise sur le marché européenne de Joenja obtenue le 22 mai 2026
Amélioration de 15 M$ de la prévision de charges opérationnelles 2026
Outlook / guidance
Expected revenue: 375 millions de dollars
Management commentary: Total revenues between US$375.0 million and US$395.0 million (0% to 5% growth), updated to reflect a US$30 million reduction compared with prior guidance.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
